Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24
BACKGROUND: The aims of this study were to compare results from a Taiwanese sub-study of the GLOBE 2303 telbivudine study and evaluate the HBV DNA kinetics. METHODS: Forty-one Taiwanese patients were treated for an additional 2 years with telbivudine. Efficacy endpoints were the same as the GLOBE st...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563525/ https://www.ncbi.nlm.nih.gov/pubmed/23234302 http://dx.doi.org/10.1186/1471-230X-12-178 |
_version_ | 1782258204157149184 |
---|---|
author | Hsu, Chao Wei Chao, You Chen Lee, Chuan Mo Chang, Ting Tsung Chen, Yi Cheng |
author_facet | Hsu, Chao Wei Chao, You Chen Lee, Chuan Mo Chang, Ting Tsung Chen, Yi Cheng |
author_sort | Hsu, Chao Wei |
collection | PubMed |
description | BACKGROUND: The aims of this study were to compare results from a Taiwanese sub-study of the GLOBE 2303 telbivudine study and evaluate the HBV DNA kinetics. METHODS: Forty-one Taiwanese patients were treated for an additional 2 years with telbivudine. Efficacy endpoints were the same as the GLOBE study. The correlations of reductions in HBV DNA levels at Week 24 were evaluated. RESULTS: All 7 HBeAg-positive patients with undetectable HBV DNA levels at Week 24 sustained this response at Year 4 with rates of ALT normalization 71%, HBeAg seroconversion 57%, and cumulative resistance 0%. Out of 16 HBeAg-negative patients with undetectable HBV DNA levels at Week 24, 11 (78%) sustained this response at Year 4 with rates of ALT normalization 83% and cumulative resistance 8.7%. There were significant correlations between reductions of DNA of ≥5 log(10) copies/mL at Week 24 with maintained PCR negativity at Years 2–4 and a lack of resistance at Year 2. CONCLUSIONS: Long-term telbivudine efficacy in Taiwanese patients was comparable to the GLOBE 2303 study. A reduction in HBV DNA levels by ≥5 log(10) copies/mL at Week 24 represented the optimal cut-off point, which may predict favourable outcomes in patients with high baseline HBV DNA levels. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00142298 (http://clinicaltrials.gov/). |
format | Online Article Text |
id | pubmed-3563525 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35635252013-02-08 Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24 Hsu, Chao Wei Chao, You Chen Lee, Chuan Mo Chang, Ting Tsung Chen, Yi Cheng BMC Gastroenterol Research Article BACKGROUND: The aims of this study were to compare results from a Taiwanese sub-study of the GLOBE 2303 telbivudine study and evaluate the HBV DNA kinetics. METHODS: Forty-one Taiwanese patients were treated for an additional 2 years with telbivudine. Efficacy endpoints were the same as the GLOBE study. The correlations of reductions in HBV DNA levels at Week 24 were evaluated. RESULTS: All 7 HBeAg-positive patients with undetectable HBV DNA levels at Week 24 sustained this response at Year 4 with rates of ALT normalization 71%, HBeAg seroconversion 57%, and cumulative resistance 0%. Out of 16 HBeAg-negative patients with undetectable HBV DNA levels at Week 24, 11 (78%) sustained this response at Year 4 with rates of ALT normalization 83% and cumulative resistance 8.7%. There were significant correlations between reductions of DNA of ≥5 log(10) copies/mL at Week 24 with maintained PCR negativity at Years 2–4 and a lack of resistance at Year 2. CONCLUSIONS: Long-term telbivudine efficacy in Taiwanese patients was comparable to the GLOBE 2303 study. A reduction in HBV DNA levels by ≥5 log(10) copies/mL at Week 24 represented the optimal cut-off point, which may predict favourable outcomes in patients with high baseline HBV DNA levels. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00142298 (http://clinicaltrials.gov/). BioMed Central 2012-12-13 /pmc/articles/PMC3563525/ /pubmed/23234302 http://dx.doi.org/10.1186/1471-230X-12-178 Text en Copyright ©2012 Hsu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Hsu, Chao Wei Chao, You Chen Lee, Chuan Mo Chang, Ting Tsung Chen, Yi Cheng Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24 |
title | Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24 |
title_full | Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24 |
title_fullStr | Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24 |
title_full_unstemmed | Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24 |
title_short | Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24 |
title_sort | efficacy of telbivudine in taiwanese chronic hepatitis b patients compared with globe extension study and predicting treatment outcome by hbv dna kinetics at week 24 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563525/ https://www.ncbi.nlm.nih.gov/pubmed/23234302 http://dx.doi.org/10.1186/1471-230X-12-178 |
work_keys_str_mv | AT hsuchaowei efficacyoftelbivudineintaiwanesechronichepatitisbpatientscomparedwithglobeextensionstudyandpredictingtreatmentoutcomebyhbvdnakineticsatweek24 AT chaoyouchen efficacyoftelbivudineintaiwanesechronichepatitisbpatientscomparedwithglobeextensionstudyandpredictingtreatmentoutcomebyhbvdnakineticsatweek24 AT leechuanmo efficacyoftelbivudineintaiwanesechronichepatitisbpatientscomparedwithglobeextensionstudyandpredictingtreatmentoutcomebyhbvdnakineticsatweek24 AT changtingtsung efficacyoftelbivudineintaiwanesechronichepatitisbpatientscomparedwithglobeextensionstudyandpredictingtreatmentoutcomebyhbvdnakineticsatweek24 AT chenyicheng efficacyoftelbivudineintaiwanesechronichepatitisbpatientscomparedwithglobeextensionstudyandpredictingtreatmentoutcomebyhbvdnakineticsatweek24 |